Market Closed - Xetra 11:40:16 2024-04-15 am EDT After market 03:21:04 pm
67.95 EUR 0.00% Intraday chart for MorphoSys AG 67.82 -0.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares DJ
Novartis: MorphoSys Board recommends tender offer CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins MT
Morphosys management bodies recommend acceptance of Novartis takeover bid DP
Novartis begins tender offer for cancer-focused MorphoSys RE
Novartis Launches Tender Offer for Germany's MorphoSys MT
Novartis initiates tender offer for MorphoSys CF
Novartis begins tender offer for cancer-focused MorphoSys RE
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance MT
INDEX-MONITOR: Morphosys and Bilfinger in the MDax as of today - Dax unchanged DP
MorphoSys AG(XTRA:MOR) added to Germany MDAX Index (Performance) CI
MorphoSys AG(XTRA:MOR) dropped from Germany SDAX (Total Return) Index CI
Morphosys sees no obstacle on its way under the Novartis umbrella DP
Transcript : MorphoSys AG, 2023 Earnings Call, Mar 14, 2024
MorphoSys Q4 EPS, Revenue Decrease MT
Morphosys with higher loss - takeover process by Novartis going according to plan DP
MorphoSys AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (MOR) MORPHOSYS AG Posts Q4 Revenue EUR59M MT
MorphoSys AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
German Regulator Clears Novartis' Takeover of MorphoSys MT
INDEX-MONITOR: Morphosys and Bilfinger move up to MDax - Dax unchanged DP
Deutsche Börse's Stoxx to Make Changes to DAX Indices MT
INDEX-MONITOR: Morphosys and Vitesco likely to swap places in March DP
Chart MorphoSys AG
More charts
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
67.95 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.59%
Consensus
  1. Stock Market
  2. Equities
  3. MOR Stock
  4. News MorphoSys AG
  5. European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading